Sen. Michael Bennet (D-CO) urged FDA to evaluate the effect the agency’s draft framework for laboratory developed tests (LDTs) might have on medical innovation and patient access to in vitro diagnostic services, laying out his concerns in a letter Thursday (April 23). The move comes as the House gears up to unveil a second draft of its 21st Century Cures draft bill, after the first iteration of the legislation broached the subject of LDTs by containing a placeholder for diagnostics...